Company: Gilead Sciences
Starting stock price: $32.16
Ending stock price: $46.01
Percent Change: 43.06%
Scoop: Gilead's big achievement of '07 was the FDA approval of Letairis, a hypertension drug that marked the company's entry into the lucrative cardiovascular space. The company reported strong Phase III results for aztreonam lysine for cystic fibrosis, and Gilead's late-stage hepatitis B treatment Viread is closing in on FDA approval. Booming sales and an EU approval of HIV treatment Atripla rounded out a great year for Gilead.
Current stock price (3/25): $51.01